Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations

British Journal of Cancer

Volumn 68, Issue 6, 1993, Pages 1115-1121

  Rojas, A ^a   Hodgkiss, R J ^a   Stratford, M R L ^a   Dennis, M F ^a   Johns, H ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOGEN; NICOTINAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER THERAPY; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; X RAY;

ADENOCARCINOMA; ANIMAL; CARBON DIOXIDE; CELL HYPOXIA; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LEAST-SQUARES ANALYSIS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED CBA; NIACINAMIDE; OXYGEN; RADIATION-SENSITIZING AGENTS; SUPPORT, NON-U.S. GOV'T;

EID: 0027368549     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1993.490     Document Type: Article

References (29)

1. CHAPLIN, D.J., HORSMAN, M.R. & AOKI, D.S. (1991). Nicotinamide, Fluosol DA and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br. J. Cancer, 63, 109-113.
2. DISCHE, S. (1983). The clinical use of hyperbaric oxygen and chemical hypoxic cell sensitizers. In The Biological Basis of Radiotherapy, Steel, G.G., Adams, G.E. & Peckham, M.J. (eds) pp. 225-237. Elsevier, Amsterdam.
3. DISCHE, S., ROJAS, A., RUGG, T., HONG, A. & MICHAEL, B.D. (1992). Carbogen breathing: a system for use in man. Br. J. Radiol., 65, 87-90.
4. 2 histography. Br. J. Cancer, 66, 919-924.
5. FOWLER, J.F. & DENEKAMP, J. (1979). A review of hypoxic cell radiosensitization in experimental tumors. Pharmac. Therap., 7, 413-444.
6. GREEN, R.G. (1970). Subclinical pellagra: its diagnosis and treatment. Schizophrenia, 2, 70-79.
7. HAUSTERMANS, K., LANDUYT, W., VANACKER, B., VAN DER KOGEL, A.J. & VAN DER SCHUEREN, E. (1992). Influence of combined use of nicotinamide and carbogen on spinal cord tolerance. Radiother. Oncol., 24 (suppl), 114.
8. HAWKINS, D.R. (1968). Treatment of schizophrenia based on the medical model. J. Schizophrenia, 2, 3-10.
9. HENDRY, J.H. (1979). Quantitation of the radiotherapeutic importance of naturally-hypoxic normal tissues from collated experiments with rodents using single doses. Int. J. Radiat. Oncol. Biol. Phys., 5, 971-976.
10. HILL, R.P. (1986). Sensitizers and radiation dose fractionation: results and interpretations. Int. J. Radiat. Oncol. Biol. Phys., 12, 1049-1054.
11. 3 therapy for schizophrenia. Canad. Psychiat. Ass. J., 16, 499-504.
12. HORSMAN, M.R., CHAPLIN, D.J. & BROWN, J.M. (1987). Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat. Res., 109, 479-489.
13. HORSMAN, M.R., CHAPLIN, D.J. & BROWN, J.M. (1989). Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat. Res., 118, 139-150.
14. HORSMAN, M.R. (1992). Carbogen and nicotinamide: expectations too high? Radiother. Oncol., 24, 121-122.
15. HORSMAN, M.R., HOYER, M., HONESS, D., DENNIS, I. & OVERGAARD, J. (1993). Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother. Oncol., 27, 131-139.
16. KJELLEN, E., JOINER, M.C., COLLIER, J.M., JOHNS, H. & ROJAS, A. (1991). A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. Oncol., 22, 81-91.
17. MARTIN, L., LARTIGAU, E., WEEGER, P., LAMBIN, P., LERIDANT, M., LUSINCHI, A., WIBAULT, P., ESCHWEGE, F., UBOINSKI, B., & GUICHARD, M. (1993). Changes in the oxygenation of head and neck tumours during carbogen breathing. Radiother. Oncol., 27, 123-130.
18. OVERGAARD, J., SAND HANSEN, H., LINDELOV, B., OVERGAARD, M., JORGENSEN, K. & RASMUSSON, B. (1991). Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish head and neck cancer study (Dahanca). Radiother. Oncol., 20, 143-149.
19. OVERGAARD, J. (1992). Importance of tissue hypoxia in radiotherapy. A meta-analysis of controlled clinical trials. Radiother. Oncol, 24 (suppl), 64.
20. ROJAS, A., CARL, U. & REGHEBI, K. (1990a). Effect of normobaric oxygen on tumor radiosensitivity: fractionated studies. Int. J. Radiat. Oncol. Biol. Phys., 18, 547-553.
21. ROJAS, A., KJELLEN, E. & JOINER, M.C. (1990b). Does nicotinamide inhibit repair of radiation damage in vivo? Br. J. Radiol., 63, 914.
22. ROJAS, A. (1992). ARCON: accelerated radiotherapy with carbogen and nicotinamide. Br. J. Radiol., 24, 174-178.
23. RUBIN, P., HANLEY, J., KEYS, H.M., MARCIAL, V. & BRADY, L. (1979). Carbogen breathing during radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 5, 1963-1970.
24. STEWART, F.A., DENEKAMP, J. & RANDHAWA, V S. (1982). Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. Br. J. Cancer, 45, 869-877.
25. STRATFORD, M.R.L. & DENNIS, M.F. (1992). High-performance liquid chromatographic determination of nicotinamide and its metabolites in human and murine plasma and urine. J. Chromatog., 582, 145-151.
26. STRATFORD, M.R.L., ROJAS, A., HALL, D.W., DENNIS, M.F., DISCHE, S., JOINER, M.C. & HODGKISS, R.J. (1992). Pharmacokinetics of nicotinamide and its effects on blood pressure, pulse, and body temperature in normal human volunteers. Radiother. Oncol, 25, 37-42.
27. VAGUE, P., PICQ, R., BERNAL, M., LASSMAN-VAGUE, V. & VIALETTES, B. (1989). Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients. Diabetol., 32, 316-321.
28. 3 (nicotinamide). New England J. Med., 289, 1180-1182.
29. ZACKHEIM, H.S., VASILY, D.B., WESTPHAL, M L. & HASTINGS, C.W. (1981). Reactions to niacinamide. J. Amer. Ac. Derm., 4, 736-737.